Potential role for second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis

Ishikawa, M; Iriyama, N; Tokuhira, M; Takaku, T; Sato, E; Sugimoto, KJ; Nakazato, T; Fujita, H; Kimura, Y; Fujioka, I; Komatsu, N; Asou, N; Kizaki, M; Hatta, Y; Kawaguchi, T

Iriyama, N (reprint author), Nihon Univ, Sch Med, Dept Med, Div Hematol & Rheumatol,Itabashi Ku, 30-1 Oyaguchi Kami Cho, Tokyo 1738610, Japan.

ONCOLOGY REPORTS, 2019; 42 (6): 2836

Abstract

Tyrosine kinase inhibitor (TKI) treatment is the standard of care for patients with chronic myeloid leukemia (CML). Even in the imatinib era, the pres......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索